Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 22% Improvement Relative Risk Death/intubation 18% primary Ventilation 7% c19early.org/mf Lalau et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? PSM retrospective 1,090 patients in France (March - April 2020) Lower mortality (p=0.16) and death/intubation (p=0.21), not stat. sig. Lalau et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216 Favors metformin Favors control
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
Lalau et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216
Lalau et al., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for.., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 2,449 hospitalized COVID-19 diabetes patients in France, 1,496 with existing metformin use, showing lower mortality with treatment. Statistical significance was reached in model 1 but not in models 2-4 which also adjust for HbA1c, eGFR, and diabetes duration, but have a lower number of patients. CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes).
Although the 22% lower mortality is not statistically significant, it is consistent with the significant 32% lower mortality [27‑37%] from meta analysis of the 46 mortality results to date.
risk of death, 22.2% lower, OR 0.78, p = 0.16, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
risk of death/intubation, 17.8% lower, OR 0.82, p = 0.21, treatment 671, control 419, day 28, model 2, propensity score matching, primary outcome, RR approximated with OR.
risk of mechanical ventilation, 6.8% lower, OR 0.93, p = 0.72, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lalau et al., 10 Dec 2020, retrospective, France, peer-reviewed, 33 authors, study period 10 March, 2020 - 10 April, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Diabetes & Metabolism 47 (2021) 101216 Available online at ScienceDirect www.sciencedirect.com Original article Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 Jean-Daniel Lalau a,b,*, Abdallah Al-Salameh a,b,*, Samy Hadjadj c, Thomas Goronflot d, Nicolas Wiernsperger e, Matthieu Pichelin c, Ingrid Allix f, Coralie Amadou g, Olivier Bourron h, Thierry Duriez i, Jean-François Gautier j, Anne Dutour k, Céline Gonfroy l, Didier Gouet m, Michael Joubert n, Ingrid Julier o, Etienne Larger p, Lucien Marchand q, Michel Marre r, Laurent Meyer s, Frédérique Olivier t, Gaëtan Prevost u, Pascale Quiniou v, Christelle Raffaitin-Cardin w, Ronan Roussel x, Pierre-Jean Saulnier y , Dominique Seret-Begue z, Charles Thivolet aa, Camille Vatier bb, Rachel Desailloud a,b, Matthieu Wargny d, Pierre Gourdy cc,1, Bertrand Cariou c,1 for the CORONADO investigators2 a Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, 80054 Amiens, France PériTox = UMR_I 01, University of Picardie Jules Verne, Amiens, France Département d’Endocrinologie, Diabétologie et Nutrition, l’institut du Thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093 Nantes Cedex 01, France d Data Clinic, INSERM, CIC 1413, PHU 11, Nantes University Hospital, Nantes, France e Association REMEDES, Ville-sur-Jarnioux, France f Département d’Endocrinologie, Diabétologie, Nutrition, CHU Angers, Angers, France g Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France h Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France i Service D’Endocrinologie, Diabétologie, CH Cholet, Cholet, France j Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France k Département d’Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France l Service d’Endocrinologie, Diabétologie, CH de Pontoise, Pontoise, France m Service de Diabétologie, Endocrinologie, Centre Hospitalier de la Rochelle, La Rochelle, France n Service Diabétologie-endocrinologie, CHU Caen, Caen, France o CH de Ales, Ales, France p Université de Paris and AP-HP, Centre Hospitalier Universitaire de Paris, Cochin Hospital, Paris, France q Département d’Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France r Clinique Ambroise Paré Neuilly-sur-Seine, Centre de Recherches des Cordelier, Université Paris Diderot, Paris, France s Service d’Endocrinologie, Diabète et Nutrition, HUS - Hôpital Civil, Strasbourg, France t Service de Diabétologie, Centre Hospitalier de Cahors, Cahors, France u Département d’Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France v CHU de Brest, Brest, France w CH Robet Boulin de Libourne, Libourne, France x Département d’Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, U-1138, Université de Paris, Paris, France y Centre d’Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France z Service de..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit